« Back to Record
Citation APA

Hoeper, M. M., White, R. J., Miller, K. K., Langley, J., Harris, J. H. N., Blair, C., Rubin, L., Vachiery, J.-L., McLaughlin, V., Barberà, J. A., Frost, A., Ghofrani, H. A., Peacock, A. J., Simonneau, G., Rosenkranz, S., & Oudiz, R. J. (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. The Lancet Respiratory Medicine, 4(11), 894-901. doi:10.1016/S2213-2600(16)30307-1


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/243885

Hoeper, M. M., White, R. J., Miller, K. K., Langley, J., Harris, J. H. N., Blair, C., Rubin, L., Vachiery, J.-L., McLaughlin, V., Barberà, J. A., Frost, A., Ghofrani, H. A., Peacock, A. J., Simonneau, G., Rosenkranz, S., & Oudiz, R. J. (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. The Lancet Respiratory Medicine, 4(11), 894-901. doi:10.1016/S2213-2600(16)30307-1